NDV-01 (sustained-release gemcitabine-docetaxel)
Phase 3WithdrawnDevelopment Stage
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder, Urologic Cancer
May 1, 2026 → Nov 1, 2029
About NDV-01 (sustained-release gemcitabine-docetaxel)
NDV-01 (sustained-release gemcitabine-docetaxel) is a phase 3 stage product being developed by Relmada Therapeutics for Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT07313891. Target conditions include Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder.
What happened to similar drugs?
20 of 20 similar drugs in Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) were approved
Hype Score Breakdown
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07342517 | Phase 3 | Withdrawn |
| NCT07464145 | Phase 3 | Recruiting |
| NCT07313891 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)